中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
CHINESE JOURNAL OF MATERNAL AND CHILD HEALTH RESEARCH
2009年
4期
445-447
,共3页
多囊卵巢综合征%来曲唑%克罗米芬%促排卵%子宫内膜
多囊卵巢綜閤徵%來麯唑%剋囉米芬%促排卵%子宮內膜
다낭란소종합정%래곡서%극라미분%촉배란%자궁내막
polycystic ovary syndrome (PCOS)%letrozole%clomiphene%ovulation induction%endometrium
目的 探讨来曲唑用于多囊卵巢综合征不孕症妇女促排卵对子宫内膜生长的影响.方法 将患多囊卵巢综合征导致不孕的60例患者,分为来曲唑组40例和克罗米芬组20例.来曲唑组从月经周期第5～9天每日口服来曲唑5mg,克罗米芬组于月经周期第5～9天每日口服克罗米芬50mg.超声监测卵泡发育及子宫内膜厚度,并于月经周期第5天、第10天和注射人绒毛膜促性腺激素日取静脉血测定雌二醇.当最大卵泡的平均直径≥18mm时,肌注人绒毛膜促性腺激素10 000U诱发排卵.观察血雌二醇水平及子宫内膜厚度的变化.结果 来曲唑组在月经周期第10天和注射人绒毛膜促性腺激素日血清雌二醇水平均显著低于克罗米芬组(t值分别为-15.6500、-15.0039,均P<0.05),来曲唑组在月经周期第10天血清雌二醇水平较第5天时下降.两组月经周期第10天子宫内膜厚度经比较无显著性差异,注射人绒毛膜促性腺激素日来曲唑组子宫内膜厚度(8.06±2.13mm)明显厚于克罗米芬组(6.43±1.18mm,t=3.1903,P=0.002).结论 来曲唑用于多囊卵巢综合征不孕症妇女促排卵时,有降低雌激素和抑制子宫内膜生长的作用,但抑制子宫内膜生长作用影响程度小于克罗米芬.
目的 探討來麯唑用于多囊卵巢綜閤徵不孕癥婦女促排卵對子宮內膜生長的影響.方法 將患多囊卵巢綜閤徵導緻不孕的60例患者,分為來麯唑組40例和剋囉米芬組20例.來麯唑組從月經週期第5～9天每日口服來麯唑5mg,剋囉米芬組于月經週期第5～9天每日口服剋囉米芬50mg.超聲鑑測卵泡髮育及子宮內膜厚度,併于月經週期第5天、第10天和註射人絨毛膜促性腺激素日取靜脈血測定雌二醇.噹最大卵泡的平均直徑≥18mm時,肌註人絨毛膜促性腺激素10 000U誘髮排卵.觀察血雌二醇水平及子宮內膜厚度的變化.結果 來麯唑組在月經週期第10天和註射人絨毛膜促性腺激素日血清雌二醇水平均顯著低于剋囉米芬組(t值分彆為-15.6500、-15.0039,均P<0.05),來麯唑組在月經週期第10天血清雌二醇水平較第5天時下降.兩組月經週期第10天子宮內膜厚度經比較無顯著性差異,註射人絨毛膜促性腺激素日來麯唑組子宮內膜厚度(8.06±2.13mm)明顯厚于剋囉米芬組(6.43±1.18mm,t=3.1903,P=0.002).結論 來麯唑用于多囊卵巢綜閤徵不孕癥婦女促排卵時,有降低雌激素和抑製子宮內膜生長的作用,但抑製子宮內膜生長作用影響程度小于剋囉米芬.
목적 탐토래곡서용우다낭란소종합정불잉증부녀촉배란대자궁내막생장적영향.방법 장환다낭란소종합정도치불잉적60례환자,분위래곡서조40례화극라미분조20례.래곡서조종월경주기제5～9천매일구복래곡서5mg,극라미분조우월경주기제5～9천매일구복극라미분50mg.초성감측란포발육급자궁내막후도,병우월경주기제5천、제10천화주사인융모막촉성선격소일취정맥혈측정자이순.당최대란포적평균직경≥18mm시,기주인융모막촉성선격소10 000U유발배란.관찰혈자이순수평급자궁내막후도적변화.결과 래곡서조재월경주기제10천화주사인융모막촉성선격소일혈청자이순수평균현저저우극라미분조(t치분별위-15.6500、-15.0039,균P<0.05),래곡서조재월경주기제10천혈청자이순수평교제5천시하강.량조월경주기제10천자궁내막후도경비교무현저성차이,주사인융모막촉성선격소일래곡서조자궁내막후도(8.06±2.13mm)명현후우극라미분조(6.43±1.18mm,t=3.1903,P=0.002).결론 래곡서용우다낭란소종합정불잉증부녀촉배란시,유강저자격소화억제자궁내막생장적작용,단억제자궁내막생장작용영향정도소우극라미분.
Objective To investigate influences of letrozole on endometrial growth of infertile women with polycystic ovary syndrome (PCOS) in ovulation induction. Methods 60 infertile women with PCOS were divided into letrozole group(n=40) and clomiphene citrate (CC) group(n=20). 40 patients in letrozole group received 5mg per day of letrozole and 20 patients in CC group received 50mg per day of CC from day 5 to day 9 of menstrual cycle respectively. Ultrasonography was used to monitor follicular development and endometrial thickness of patients in the two groups. And serum level of estradiol (E2) of all patients was detected on day 5 and day 10 of menstrual cycle and hCG injection day. When diameter of the largest follicle was ≥18mm, the patient was given 10000 U of hCG intramuscularly to induce ovulation. The serum level of E2 and endometrial thickness of all patients in the two groups were compared. Results The level of E2 of patients in the letrozole group was significantly lower than CC group on day 10 of menstrual cycle and hCG injection day respectively (t=-15.6500, -15.0039 respectively,both P<0.05). Furthermore, in the letrozole group, the serum level of E2 on 10 day of menstrual cycle of the patients was lower than that on day 5 of menstrual cycle. In endometrial thickness of patients on day 10 of menstrual cycle there was no significant difference between the two groups, but the endometria of patients in the letrozole group (8.06±2.13mm) were significantly thicker than CC group (6.43±1.18mm) on the hCG injection day(t=3.1903,P=0.002). Conclusion Letrozole could decrease serum level of E2 and inhibit growth of endometrium of infertile women with PCOS in ovulation induction, however, its inhibitory role for endometrial growth is weaker than CC.
